Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.755 USD | -1.05% | +13.83% | -57.39% |
26/04 | AbbVie raises annual profit forecast on strong Skyrizi sales | RE |
12/04 | Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-57.39% | 395M | |
-3.93% | 86.16B | |
+2.76% | 40.17B | |
-16.99% | 31.47B | |
+54.44% | 25.24B | |
-12.14% | 15.82B | |
-9.12% | 11.96B | |
-15.48% | 11.89B | |
-42.56% | 11.61B | |
+4.87% | 8.84B |
- Stock Market
- Equities
- RVNC Stock
- News Revance Therapeutics, Inc.
- Barclays Adjusts Revance Therapeutics' Price Target to $22 From $33, Maintains Overweight Rating